Ulcerative Colitis - Pipeline Review, H1 2015

Published: Jan, 2015 | Pages: 359 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Ulcerative Colitis - Pipeline Review, H1 2015

Summary

Global Markets Direct's, 'Ulcerative Colitis - Pipeline Review, H1 2015', provides an overview of the Ulcerative Colitis's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Ulcerative Colitis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Ulcerative Colitis and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Ulcerative Colitis
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Ulcerative Colitis and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Ulcerative Colitis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Ulcerative Colitis pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Ulcerative Colitis
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Ulcerative Colitis pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents
Table of Contents 2
List of Tables 7
List of Figures 9
Introduction 10
Global Markets Direct Report Coverage 10
Ulcerative Colitis Overview 11
Therapeutics Development 12
Pipeline Products for Ulcerative Colitis - Overview 12
Pipeline Products for Ulcerative Colitis - Comparative Analysis 13
Ulcerative Colitis - Therapeutics under Development by Companies 14
Ulcerative Colitis - Therapeutics under Investigation by Universities/Institutes 21
Ulcerative Colitis - Pipeline Products Glance 22
Late Stage Products 22
Clinical Stage Products 23
Early Stage Products 24
Unknown Stage Products 25
Ulcerative Colitis - Products under Development by Companies 26
Ulcerative Colitis - Products under Investigation by Universities/Institutes 33
Ulcerative Colitis - Companies Involved in Therapeutics Development 34
Ajinomoto Pharmaceuticals Co., Ltd. 34
AlphaMab Co., Ltd 35
Altheus Therapeutics, Inc. 36
Am-Pharma B.V. 37
Amgen Inc. 38
Astellas Pharma Inc. 39
AstraZeneca PLC 40
Athersys, Inc. 41
Atlantic Healthcare plc 42
Avaxia Biologics, Inc. 43
Biocon Limited 44
BioLineRx, Ltd. 45
Bristol-Myers Squibb Company 46
Celgene Corporation 47
Cellceutix Corporation 48
Celltrion, Inc. 49
ChemoCentryx, Inc. 50
ChironWells GmbH 51
Cosmo Pharmaceuticals S.p.A 52
Dr. Falk Pharma GmbH 53
Drais Pharmaceuticals, Inc. 54
Effimune SAS 55
Emergent BioSolutions Inc. 56
Enceladus Pharmaceuticals BV 57
Epirus Biopharmaceuticals, Inc. 58
Euroscreen S.A. 59
Farmacija d.o.o. Tuzla 60
Flexion Therapeutics, Inc. 61
Galapagos NV 62
Genentech, Inc. 63
Genfit SA 64
Genor BioPharma Co., Ltd. 65
Gilead Sciences, Inc. 66
GT Biologics Limited 67
GW Pharmaceuticals plc 68
iCo Therapeutics Inc. 69
InDex Pharmaceuticals AB 70
INOXIA Lifesciences GmbH 71
Invion Limited 72
Johnson & Johnson 73
Kaken Pharmaceutical Co., Ltd. 74
LIPID THERAPEUTICS GmbH 75
LTT Bio-Pharma Co., Ltd. 76
Mabion SA 77
Medestea Research & Production S.p.A. 78
Morphotek, Inc. 79
Nogra Pharma Limited 80
Oncobiologics, Inc. 81
Pfizer Inc. 82
Pluristem Therapeutics Inc. 83
ProtAb Ltd 84
Qu Biologics Inc. 85
Receptos, Inc. 86
Sandoz Inc. 87
Sanofi 88
Sigmoid Pharma Limited 89
Stelic Institute & Co. 90
sterna biologicals Gmbh & Co KG 91
Synergy Pharmaceuticals, Inc. 92
Takeda Pharmaceutical Company Limited 93
TiGenix NV 94
Tillotts Pharma AG 95
Trino Therapeutics Ltd 96
Vascular Biogenics Ltd. 97
Ventria Bioscience 98
Zyngenia, Inc. 99
Ulcerative Colitis - Therapeutics Assessment 100
Assessment by Monotherapy Products 100
Assessment by Combination Products 101
Assessment by Target 102
Assessment by Mechanism of Action 106
Assessment by Route of Administration 109
Assessment by Molecule Type 111
Drug Profiles 113
(mesalamine + N-acetylcysteine) - Drug Profile 113
(metenkefalin + tridecactide) - Drug Profile 115
AB-0045 - Drug Profile 116
abrilumab - Drug Profile 117
ABS-11 - Drug Profile 119
adalimumab biosimilar - Drug Profile 120
adalimumab biosimilar - Drug Profile 122
adalimumab biosimilar - Drug Profile 123
adalimumab biosimilar - Drug Profile 124
adalimumab biosimilar - Drug Profile 125
adalimumab biosimilar - Drug Profile 126
adalimumab biosimilar - Drug Profile 127
adalimumab biosimilar - Drug Profile 128
AJM-300 - Drug Profile 129
alicaforsen sodium - Drug Profile 131
Anatabine - Drug Profile 132
apremilast - Drug Profile 133
ASP-3291 - Drug Profile 136
AVX-470 - Drug Profile 137
AW/EPO-002 - Drug Profile 138
AW/EPO-003 - Drug Profile 139
AW/EPOPD-01 - Drug Profile 140
AW/EPOPD-02 - Drug Profile 141
AW/EPOPD-06 - Drug Profile 142
bertilimumab - Drug Profile 143
BL-7040 - Drug Profile 145
BLI-1006 - Drug Profile 148
brilacidin - Drug Profile 149
budesonide - Drug Profile 151
budesonide ER - Drug Profile 154
budesonide ER - Drug Profile 156
CCX-507 - Drug Profile 157
Cell Therapy for Ulcerative Colitis and Inflammatory Bowel Disease - Drug Profile 158
CNDO-201 - Drug Profile 159
Cx-602 - Drug Profile 161
cyclosporine CR - Drug Profile 162
DIMS-0150 - Drug Profile 163
Drugs for Ulcerative Colitis - Drug Profile 165
eldelumab - Drug Profile 166
enalaprilat - Drug Profile 168
ES-210 - Drug Profile 169
ESN-282 - Drug Profile 170
etrolizumab - Drug Profile 171
FX-003 - Drug Profile 173
GED-0507 - Drug Profile 174
GFT-505 - Drug Profile 175
GLPG-0974 - Drug Profile 178
GLPG-1205 - Drug Profile 179
GS-5745 - Drug Profile 180
GWP-42003 - Drug Profile 181
hyaluronate sodium - Drug Profile 183
IAC VITA - Drug Profile 184
infliximab - Drug Profile 186
infliximab biosimilar - Drug Profile 188
infliximab biosimilar - Drug Profile 190
infliximab biosimilar - Drug Profile 191
infliximab biosimilar - Drug Profile 192
INV-103 - Drug Profile 193
INV-88 - Drug Profile 195
KAG-308 - Drug Profile 196
KANAb-071 - Drug Profile 197
Leukothera - Drug Profile 198
Low Molecular Weight Heparin - Drug Profile 199
LT-0011 - Drug Profile 200
LT-02 - Drug Profile 201
MD-707 - Drug Profile 202
mesalamine - Drug Profile 203
mesalamine - Drug Profile 204
mesalamine CR - Drug Profile 205
mesalamine ER - Drug Profile 206
Monoclonal Antibodies to Antagonize Metallothioneins for Ulcerative Colitis and Crohn's Disease - Drug Profile 208
Monoclonal Antibodies to Inhibit TNFR25 for Gastrointestinal Disorders and Asthma - Drug Profile 210
Monoclonal Antibody to Inhibit Ang-2 and TNF-a for Ulcerative Colitis, Arthritis and Inflammatory Disease - Drug Profile 211
Monoclonal Antibody to Inhibit CD3 for Autoimmune Disorders, CNS Disorders, Infectious Diseases, Liver Diseases, Metabolic Disorders and Cardiovascular Diseases - Drug Profile 212
MultiStem - Drug Profile 214
naltrexone - Drug Profile 217
Nanocort - Drug Profile 218
peficitinib - Drug Profile 220
Peptides to Inhibit IL-1 Beta for Ulcerative Colitis and Crohn's Disease - Drug Profile 222
PF-00547659 - Drug Profile 223
PH-44 - Drug Profile 225
PH-46A - Drug Profile 226
PH-5 - Drug Profile 227
Prozumab - Drug Profile 228
QBECO - Drug Profile 229
Recombinant Human Alkaline Phosphatase - Drug Profile 231
Rosburix - Drug Profile 233
RPC-1063 - Drug Profile 234
SAR-252067 - Drug Profile 236
SB-012 - Drug Profile 237
SD-010 - Drug Profile 238
Small Molecule for Ulcerative Colitis and Inflammation - Drug Profile 239
Small Molecule to Agonize OP3 Receptor for Crohn's Disease and Ulcerative Colitis - Drug Profile 240
Small Molecules for Gastrointestinal Disorders - Drug Profile 241
Small Molecules to Inhibit IL-13 for Ulcerative Colitis - Drug Profile 242
Small Molecules to Target IL-13 for Ulcerative Colitis - Drug Profile 243
SP-333 - Drug Profile 244
Stem Cell Therapy for Inflammatory Bowel Disease - Drug Profile 245
STNM-01 - Drug Profile 246
TAK-114 - Drug Profile 247
tofacitinib - Drug Profile 249
TP-10 - Drug Profile 253
VB-201 - Drug Profile 254
VEDA-1209 - Drug Profile 256
vedolizumab - Drug Profile 257
VEN-120 - Drug Profile 259
Ulcerative Colitis - Recent Pipeline Updates 260
Ulcerative Colitis - Dormant Projects 337
Ulcerative Colitis - Discontinued Products 340
Ulcerative Colitis - Product Development Milestones 342
Featured News & Press Releases 342
Appendix 350
Methodology 350
Coverage 350
Secondary Research 350
Primary Research 350
Expert Panel Validation 350
Contact Us 351
Disclaimer 351

List of Tables
Number of Products under Development for Ulcerative Colitis, H1 2015 20
Number of Products under Development for Ulcerative Colitis - Comparative Analysis, H1 2015 21
Number of Products under Development by Companies, H1 2015 23
Number of Products under Development by Companies, H1 2015 (Contd..1) 24
Number of Products under Development by Companies, H1 2015 (Contd..2) 25
Number of Products under Development by Companies, H1 2015 (Contd..3) 26
Number of Products under Development by Companies, H1 2015 (Contd..4) 27
Number of Products under Development by Companies, H1 2015 (Contd..5) 28
Number of Products under Investigation by Universities/Institutes, H1 2015 29
Comparative Analysis by Late Stage Development, H1 2015 30
Comparative Analysis by Clinical Stage Development, H1 2015 31
Comparative Analysis by Early Stage Development, H1 2015 32
Comparative Analysis by Unknown Stage Development, H1 2015 33
Products under Development by Companies, H1 2015 34
Products under Development by Companies, H1 2015 (Contd..1) 35
Products under Development by Companies, H1 2015 (Contd..2) 36
Products under Development by Companies, H1 2015 (Contd..3) 37
Products under Development by Companies, H1 2015 (Contd..4) 38
Products under Development by Companies, H1 2015 (Contd..5) 39
Products under Development by Companies, H1 2015 (Contd..6) 40
Products under Investigation by Universities/Institutes, H1 2015 41
Ulcerative Colitis - Pipeline by Ajinomoto Pharmaceuticals Co., Ltd., H1 2015 42
Ulcerative Colitis - Pipeline by AlphaMab Co., Ltd, H1 2015 43
Ulcerative Colitis - Pipeline by Altheus Therapeutics, Inc., H1 2015 44
Ulcerative Colitis - Pipeline by Am-Pharma B.V., H1 2015 45
Ulcerative Colitis - Pipeline by Amgen Inc., H1 2015 46
Ulcerative Colitis - Pipeline by Astellas Pharma Inc., H1 2015 47
Ulcerative Colitis - Pipeline by AstraZeneca PLC, H1 2015 48
Ulcerative Colitis - Pipeline by Athersys, Inc., H1 2015 49
Ulcerative Colitis - Pipeline by Atlantic Healthcare plc, H1 2015 50
Ulcerative Colitis - Pipeline by Avaxia Biologics, Inc., H1 2015 51
Ulcerative Colitis - Pipeline by Biocon Limited, H1 2015 52
Ulcerative Colitis - Pipeline by BioLineRx, Ltd., H1 2015 53
Ulcerative Colitis - Pipeline by Bristol-Myers Squibb Company, H1 2015 54
Ulcerative Colitis - Pipeline by Celgene Corporation, H1 2015 55
Ulcerative Colitis - Pipeline by Cellceutix Corporation, H1 2015 56
Ulcerative Colitis - Pipeline by Celltrion, Inc., H1 2015 57
Ulcerative Colitis - Pipeline by ChemoCentryx, Inc., H1 2015 58
Ulcerative Colitis - Pipeline by ChironWells GmbH, H1 2015 59
Ulcerative Colitis - Pipeline by Cosmo Pharmaceuticals S.p.A, H1 2015 60
Ulcerative Colitis - Pipeline by Dr. Falk Pharma GmbH, H1 2015 61
Ulcerative Colitis - Pipeline by Drais Pharmaceuticals, Inc., H1 2015 62
Ulcerative Colitis - Pipeline by Effimune SAS, H1 2015 63
Ulcerative Colitis - Pipeline by Emergent BioSolutions Inc., H1 2015 64
Ulcerative Colitis - Pipeline by Enceladus Pharmaceuticals BV, H1 2015 65
Ulcerative Colitis - Pipeline by Epirus Biopharmaceuticals, Inc., H1 2015 66
Ulcerative Colitis - Pipeline by Euroscreen S.A., H1 2015 67
Ulcerative Colitis - Pipeline by Farmacija d.o.o. Tuzla, H1 2015 68
Ulcerative Colitis - Pipeline by Flexion Therapeutics, Inc., H1 2015 69
Ulcerative Colitis - Pipeline by Galapagos NV, H1 2015 70
Ulcerative Colitis - Pipeline by Genentech, Inc., H1 2015 71
Ulcerative Colitis - Pipeline by Genfit SA, H1 2015 72
Ulcerative Colitis - Pipeline by Genor BioPharma Co., Ltd., H1 2015 73
Ulcerative Colitis - Pipeline by Gilead Sciences, Inc., H1 2015 74
Ulcerative Colitis - Pipeline by GT Biologics Limited, H1 2015 75
Ulcerative Colitis - Pipeline by GW Pharmaceuticals plc, H1 2015 76
Ulcerative Colitis - Pipeline by iCo Therapeutics Inc., H1 2015 77
Ulcerative Colitis - Pipeline by InDex Pharmaceuticals AB, H1 2015 78
Ulcerative Colitis - Pipeline by INOXIA Lifesciences GmbH, H1 2015 79
Ulcerative Colitis - Pipeline by Invion Limited, H1 2015 80
Ulcerative Colitis - Pipeline by Johnson & Johnson, H1 2015 81
Ulcerative Colitis - Pipeline by Kaken Pharmaceutical Co., Ltd., H1 2015 82
Ulcerative Colitis - Pipeline by LIPID THERAPEUTICS GmbH, H1 2015 83
Ulcerative Colitis - Pipeline by LTT Bio-Pharma Co., Ltd., H1 2015 84
Ulcerative Colitis - Pipeline by Mabion SA, H1 2015 85
Ulcerative Colitis - Pipeline by Medestea Research & Production S.p.A., H1 2015 86
Ulcerative Colitis - Pipeline by Morphotek, Inc., H1 2015 87
Ulcerative Colitis - Pipeline by Nogra Pharma Limited, H1 2015 88
Ulcerative Colitis - Pipeline by Oncobiologics, Inc., H1 2015 89
Ulcerative Colitis - Pipeline by Pfizer Inc., H1 2015 90
Ulcerative Colitis - Pipeline by Pluristem Therapeutics Inc., H1 2015 91
Ulcerative Colitis - Pipeline by ProtAb Ltd, H1 2015 92
Ulcerative Colitis - Pipeline by Qu Biologics Inc., H1 2015 93
Ulcerative Colitis - Pipeline by Receptos, Inc., H1 2015 94
Ulcerative Colitis - Pipeline by Sandoz Inc., H1 2015 95
Ulcerative Colitis - Pipeline by Sanofi, H1 2015 96
Ulcerative Colitis - Pipeline by Sigmoid Pharma Limited, H1 2015 97
Ulcerative Colitis - Pipeline by Stelic Institute & Co., H1 2015 98
Ulcerative Colitis - Pipeline by sterna biologicals Gmbh & Co KG, H1 2015 99
Ulcerative Colitis - Pipeline by Synergy Pharmaceuticals, Inc., H1 2015 100
Ulcerative Colitis - Pipeline by Takeda Pharmaceutical Company Limited, H1 2015 101
Ulcerative Colitis - Pipeline by TiGenix NV, H1 2015 102
Ulcerative Colitis - Pipeline by Tillotts Pharma AG, H1 2015 103
Ulcerative Colitis - Pipeline by Trino Therapeutics Ltd, H1 2015 104
Ulcerative Colitis - Pipeline by Vascular Biogenics Ltd., H1 2015 105
Ulcerative Colitis - Pipeline by Ventria Bioscience, H1 2015 106
Ulcerative Colitis - Pipeline by Zyngenia, Inc., H1 2015 107
Assessment by Monotherapy Products, H1 2015 108
Assessment by Combination Products, H1 2015 109
Number of Products by Stage and Target, H1 2015 111
Number of Products by Stage and Mechanism of Action, H1 2015 115
Number of Products by Stage and Route of Administration, H1 2015 118
Number of Products by Stage and Molecule Type, H1 2015 120
Ulcerative Colitis Therapeutics - Recent Pipeline Updates, H1 2015 268
Ulcerative Colitis - Dormant Projects, H1 2015 345
Ulcerative Colitis - Discontinued Products, H1 2015 348
Ulcerative Colitis - Discontinued Products (Contd..1), H1 2015 349